Thiazolidinedione treatment is not associated with an increased risk of major adverse cardiovascular events

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1643, 2008-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ephedra: risk of adverse cardiovascular events

By  

Inpharma, Vol. 1, Iss. 1325, 2002-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Is the Use of Selective COX Inhibitors Associated with an Increased Risk of Cardiovascular Events?

By  

Heart Drug, Vol. 4, Iss. 2, 2004-05 ,pp. : 92-95

Karger

Access to resources Recommend Favorite

Inhaled anticholinergics: increased risk of major adverse CV events?

By  

Inpharma, Vol. 1, Iss. 1658, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

A meta-analysis has identified a significantly increased risk of serious adverse events and treatment discontinuation in patients receiving telaprevir

By  

Reactions Weekly, Vol. 1, Iss. 1419, 2012-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Treatment-emergent adverse events associated with atypical antipsychotics

By Cha Danielle S   McIntyre Roger S  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 11, 2012-08 ,pp. : 1587-1598

Informa Healthcare

Access to resources Recommend Favorite